Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity (2020 - 2023)

Historic Liabilities and Shareholders Equity for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $494.7 million.

  • Cullinan Therapeutics' Liabilities and Shareholders Equity fell 1985.14% to $494.7 million in Q3 2023 from the same period last year, while for Dec 2023 it was $1.5 billion, marking a year-over-year decrease of 3291.12%. This contributed to the annual value of $561.1 million for FY2022, which is 2834.77% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Liabilities and Shareholders Equity of $494.7 million as of Q3 2023, which was down 1985.14% from $522.0 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Liabilities and Shareholders Equity registered a high of $667.2 million during Q2 2022, and its lowest value of $214.7 million during Q4 2020.
  • For the 4-year period, Cullinan Therapeutics' Liabilities and Shareholders Equity averaged around $488.7 million, with its median value being $487.2 million (2021).
  • As far as peak fluctuations go, Cullinan Therapeutics' Liabilities and Shareholders Equity surged by 10361.84% in 2021, and later tumbled by 2177.07% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $214.7 million in 2020, then skyrocketed by 103.62% to $437.2 million in 2021, then grew by 28.35% to $561.1 million in 2022, then decreased by 11.84% to $494.7 million in 2023.
  • Its Liabilities and Shareholders Equity stands at $494.7 million for Q3 2023, versus $522.0 million for Q2 2023 and $515.0 million for Q1 2023.